NeoGenomics Reports Strong 2025 Revenue Growth, Positive 2026 Guidance, and Strategic Product Launch
NEO has more than doubled off its 52-week low of $4.72.
Summary
NeoGenomics reported strong double-digit revenue growth for Q4 and full-year 2025, alongside positive 2026 guidance projecting significant reductions in net loss and continued Adjusted EBITDA growth, bolstered by strategic product launches and patent resolution.
Key Events · Earnings and Guidance · NEO
-
Strong Q4 and Full-Year 2025 Revenue Growth
Consolidated revenue increased 11% in Q4 to $190 million and 10% for the full year to $727 million, driven by clinical volumes and higher-value tests.
-
Improved Profitability Metrics
Q4 net loss decreased 36% to $10 million, and full-year adjusted EBITDA grew 9% to $43 million, indicating an improving trend in operational profitability.
-
Positive 2026 Financial Guidance
The company projects 9-10% revenue growth, a 42-54% reduction in net loss, and 27-31% growth in Adjusted EBITDA for fiscal year 2026.
-
Strategic Progress with New Product Launch
NeoGenomics successfully resolved RaDaR ST patent litigation and anticipates the imminent clinical launch of its RaDaR ST MRD assay, targeting a significant molecular residual disease monitoring market.
Analysis · NEO · Industrial Applications And Services
This 8-K provides the final Q4 and full-year 2025 financial results and crucial 2026 guidance, building on the preliminary revenue figures disclosed in January. The company demonstrated solid double-digit revenue growth in 2025, driven by clinical volumes and a shift towards higher-value tests like NGS. While the GAAP net loss increased for the full year, the fourth quarter showed a significant reduction in net loss, and the 2026 guidance projects a substantial improvement in profitability, with a projected 42-54% reduction in net loss and strong growth in Adjusted EBITDA. The successful resolution of patent litigation and the upcoming launch of the RaDaR ST MRD assay in a multi-billion dollar market further bolster the company's long-term growth prospects and strategic positioning. Investors should monitor the execution of the RaDaR ST launch and the company's progress towards its 2026 financial targets.
At the time of this filing, NEO was trading at $11.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $4.72 to $14.73. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.